AFM
VIRX

Anson Funds Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Anson Funds Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-214
Closed -$40K – 86
2015
Q4 		$40K Buy
+214
New +$40K 0.01% 93

Other funds holding VIRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Anson Funds Management's VIRX Position: Q1 2016 in Review

Anson Funds Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2016, closing a stake of 214 shares — an estimated $40K sold.

Anson Funds Management first reported a position in VIRX in Q4 2015 and held it in 1 quarter. The position peaked at $40K in Q4 2015. 56 funds tracked by Wall St. Rank hold VIRX as of Q1 2016.

  • Anson Funds Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Anson Funds Management sold 214 Viracta Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $40K.
  • Anson Funds Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2015 and held it in 1 quarter.
  • Anson Funds Management's Viracta Therapeutics, Inc. Common Stock position peaked at $40K in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Anson Funds Management's 13F filing for Q1 2016, filed 13 May 2016.